急性へん桃炎，急性気管支炎に対するセファドロキシルとセファレキシンの二重盲検比較試験に対する臨床評価

DOI Web Site

書誌事項

タイトル別名
  • CLINICAL EVALUATION OF CEFADROXIL AND CEPHALEXIN ON ACUTE TONSILLITIS AND ACUTE BRONCHITIS BY DOUBLE BLIND METHOD
  • キュウセイ ヘントウエン キュウセイ キカンシエン ニ タイスル Cefadr

この論文をさがす

抄録

For the purpose to compare the clinical efficacy and side effect of cefadroxil (abbreviated hereinafter as CDX) and cephalexin (abbreviated hereinafter as CEX) in acute tonsillitis and acute bronchitis, CDX and CEX were administered orally for 6 days at the daily dose of 750 mg (divided into 3) and 1, 000 mg (divided into 4) respectively, and clinical efficacy, side effect and utility were compared between two drugs by double blind method, and the following results were obtained.<BR>1. In acute tonsillitis, CDX (daily dose of 750 mg) tended to be superior significantly on swelling and pus fur by the examination (judged by physician in charge) on 5 th day of administration in comparison with CEX (daily dose of 1, 000 mg), and CDX was superior significantly to CEX in erythrocyte sedimentation rate on 3 rd and 5 th day. Furthermore, CDX was superior significantly in general improvement (judged by both physician in charge and committee). On the other hand, in the utility rate, CDX group showed to be slightly higher than CEX, as the rate was 86.7% in CDX group while 84.2% in CEX group.<BR>2. In acute bronchitis, CDX administration (daily dose of 750 mg) was almost equal or slightly superior on general improvement and each symptom improvement in comparison with CEX administration (daily dose of 1, 000 mg).<BR>3. Frequency of side effects was less in CDX group than in CEX group, though no significant diference was noticed.<BR>4. Utility of the drug showed no significant difference between two drug groups both in acute tonsillitis and acute bronchitis.

収録刊行物

詳細情報 詳細情報について

問題の指摘

ページトップへ